152 related articles for article (PubMed ID: 37339170)
21. Design, Synthesis, and Pharmacological Evaluation of Multisubstituted Pyrido[4,3-
Xiao X; Feng J; Ma J; Xia X; Liu X; Zhang J; Ding C; Pang X; Zhang A
J Med Chem; 2023 Nov; 66(22):15524-15549. PubMed ID: 37921024
[TBL] [Abstract][Full Text] [Related]
22. Discovery of Prodrug of MRTX1133 as an Oral Therapy for Cancers with KRAS
Ji X; Li Y; Kong X; Chen D; Lu J
ACS Omega; 2023 Feb; 8(7):7211-7221. PubMed ID: 36844555
[TBL] [Abstract][Full Text] [Related]
23. A requirement for wild-type Ras isoforms in mutant KRas-driven signalling and transformation.
Bentley C; Jurinka SS; Kljavin NM; Vartanian S; Ramani SR; Gonzalez LC; Yu K; Modrusan Z; Du P; Bourgon R; Neve RM; Stokoe D
Biochem J; 2013 Jun; 452(2):313-20. PubMed ID: 23496764
[TBL] [Abstract][Full Text] [Related]
24. Next batter up! Targeting cancers with KRAS-G12D mutations.
Zeissig MN; Ashwood LM; Kondrashova O; Sutherland KD
Trends Cancer; 2023 Nov; 9(11):955-967. PubMed ID: 37591766
[TBL] [Abstract][Full Text] [Related]
25. Multiple Strategies to Develop Small Molecular KRAS Directly Bound Inhibitors.
Zhou X; Ji Y; Zhou J
Molecules; 2023 Apr; 28(8):. PubMed ID: 37110848
[TBL] [Abstract][Full Text] [Related]
26. Unique dependence on Sos1 in
You X; Kong G; Ranheim EA; Yang D; Zhou Y; Zhang J
Blood; 2018 Dec; 132(24):2575-2579. PubMed ID: 30377195
[TBL] [Abstract][Full Text] [Related]
27. Precise and efficient silencing of mutant Kras
Jiang W; Li H; Liu X; Zhang J; Zhang W; Li T; Liu L; Yu X
Theranostics; 2020; 10(25):11507-11519. PubMed ID: 33052229
[No Abstract] [Full Text] [Related]
28. With a little help from my T friends: T cells increase efficacy of KRAS (G12D) inhibitors.
Mainardi S
Cell Rep Med; 2023 Feb; 4(2):100950. PubMed ID: 36812887
[TBL] [Abstract][Full Text] [Related]
29. SP174 Antibody Lacks Specificity for NRAS Q61R and Cross-Reacts With HRAS and KRAS Q61R Mutant Proteins in Malignant Melanoma.
Felisiak-Goląbek A; Inaguma S; Kowalik A; Wasąg B; Wang ZF; Zięba S; Pięciak L; Ryś J; Kopczynski J; Sarlomo-Rikala M; Góźdź S; Lasota J; Miettinen M
Appl Immunohistochem Mol Morphol; 2018 Jan; 26(1):40-45. PubMed ID: 29206715
[TBL] [Abstract][Full Text] [Related]
30. Discovery of Novel Noncovalent KRAS G12D Inhibitors through Structure-Based Virtual Screening and Molecular Dynamics Simulations.
Du Z; Tu G; Gong Y; Fu X; Wu Q; Long G
Molecules; 2024 Mar; 29(6):. PubMed ID: 38542866
[TBL] [Abstract][Full Text] [Related]
31. Oncogenic Kras
Mahadevan KK; McAndrews KM; LeBleu VS; Yang S; Lyu H; Li B; Sockwell AM; Kirtley ML; Morse SJ; Moreno Diaz BA; Kim MP; Feng N; Lopez AM; Guerrero PA; Sugimoto H; Arian KA; Ying H; Barekatain Y; Kelly PJ; Maitra A; Heffernan TP; Kalluri R
bioRxiv; 2023 Feb; ():. PubMed ID: 36824971
[TBL] [Abstract][Full Text] [Related]
32. Non-Redundant and Overlapping Oncogenic Readouts of Non-Canonical and Novel Colorectal Cancer KRAS and NRAS Mutants.
Alcantara KMM; Malapit JRP; Yu RTD; Garrido JAMG; Rigor JPT; Angeles AKJ; Cutiongco-de la Paz EM; Garcia RL
Cells; 2019 Dec; 8(12):. PubMed ID: 31816869
[TBL] [Abstract][Full Text] [Related]
33. Pan-KRAS inhibitor disables oncogenic signalling and tumour growth.
Kim D; Herdeis L; Rudolph D; Zhao Y; Böttcher J; Vides A; Ayala-Santos CI; Pourfarjam Y; Cuevas-Navarro A; Xue JY; Mantoulidis A; Bröker J; Wunberg T; Schaaf O; Popow J; Wolkerstorfer B; Kropatsch KG; Qu R; de Stanchina E; Sang B; Li C; McConnell DB; Kraut N; Lito P
Nature; 2023 Jul; 619(7968):160-166. PubMed ID: 37258666
[TBL] [Abstract][Full Text] [Related]
34. Activation Of Wild-Type Hras Suppresses The Earliest Stages Of Pancreatic Cancer.
Weyandt J
Redox Biol; 2015 Aug; 5():414. PubMed ID: 28162272
[TBL] [Abstract][Full Text] [Related]
35. Expanding the Reach of Precision Oncology by Drugging All KRAS Mutants.
Hofmann MH; Gerlach D; Misale S; Petronczki M; Kraut N
Cancer Discov; 2022 Apr; 12(4):924-937. PubMed ID: 35046095
[TBL] [Abstract][Full Text] [Related]
36. KRAS-G12D mutation drives immune suppression and the primary resistance of anti-PD-1/PD-L1 immunotherapy in non-small cell lung cancer.
Liu C; Zheng S; Wang Z; Wang S; Wang X; Yang L; Xu H; Cao Z; Feng X; Xue Q; Wang Y; Sun N; He J
Cancer Commun (Lond); 2022 Sep; 42(9):828-847. PubMed ID: 35811500
[TBL] [Abstract][Full Text] [Related]
37. State-of-the-art and upcoming trends in RAS-directed therapies in gastrointestinal malignancies.
Vanclooster P; Seghers S; Prenen H
Curr Opin Oncol; 2024 Jul; 36(4):313-319. PubMed ID: 38726828
[TBL] [Abstract][Full Text] [Related]
38. More to the RAS Story: KRAS
Lietman CD; Johnson ML; McCormick F; Lindsay CR
Am Soc Clin Oncol Educ Book; 2022 Apr; 42():1-13. PubMed ID: 35561303
[TBL] [Abstract][Full Text] [Related]
39. [The Effect of KRAS on Proliferation and Apoptosis of T-ALL Cell Lines].
Liu ZY; Shu Y; Fu G; Su HY; Zhu D; Zeng LM; Ma DY; Zou L
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2022 Aug; 30(4):1040-1048. PubMed ID: 35981360
[TBL] [Abstract][Full Text] [Related]
40. Identification of novel peptide inhibitors for oncogenic KRAS G12D as therapeutic options using mutagenesis-based remodeling and MD simulations.
Samad A; Khurshid B; Mahmood A; Rehman AU; Khalid A; Abdalla AN; Algarni AS; Wadood A
J Biomol Struct Dyn; 2023; 41(22):13425-13437. PubMed ID: 37010994
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
